Some compounding-pharmacy products combine tesamorelin (GHRH 1-44) with TB-500, CJC-1295, and ipamorelin, marketing a “four-way” GH-plus-recovery protocol. The only component with FDA approval is tesamorelin (HIV-associated lipodystrophy). The combination is not supported by human clinical trial evidence.